On May 21, BrainAurora-B declined 8.8% in regular trading, trading at HK$3.14/share, with trading volume of HK$160 million. The stock gave back a significant portion of gains accumulated earlier this week when shares surged as much as 55% on brain-computer interface (BCI) sector momentum.

The prior rally was triggered by the May 18 announcement that China officially launched its first 128-channel fully implantable invasive BCI system multi-center clinical trial (LEAP study), led by Capital Medical University-affiliated Beijing Tiantan Hospital with 11 medical institutions participating nationwide. The trial, sponsored by Beijing Zhiran Medical Technology, marks a milestone in Chinas self-developed high-throughput invasive BCI technology entering clinical translation. Additionally, Elon Musk announced Neuralink plans to conduct its first blindness-treatment BCI implant surgery this year. BrainAurora-B closed at HK$4.10 on May 19 (up 34.43%) and remained elevated on May 20 before the current session correction, suggesting profit-taking following the speculative spike.

BrainAurora Medical Technology is an investment holding company primarily providing cognitive impairment digital therapeutics integrated software solutions to hospitals, enabling clinical assessment and intervention for patients with cognitive disorders caused by vascular diseases, neurodegenerative diseases, and psychiatric conditions.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)